Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ryvu Therapeutics SA (9Y4) Stock Price & Analysis

2 Followers

9Y4 Stock Chart & Stats

€3.54-€0.01(-0.28%)
At close: 5:30 PM GMT+1
€5€10€15Jan 24Dec 13Feb 4Dec 22
Day’s Range
EUR 3.54 - EUR 3.54
52-Week Range
EUR 3.11 - EUR 6.98
Previous Close
EUR 3.55
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 90.29M
Enterprise Value
EUR 318.33M
Total Cash (Recent Filing)
EUR 74.74M
Total Debt (Recent Filing)
EUR 74.94M
Price to Earnings (P/E)
―
Beta
0.51
Next Earnings
Mar 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit Margin

A strong gross profit margin suggests effective cost management and pricing power, which can support future profitability as the company scales its operations.

Cash Flow Growth

Positive free cash flow growth indicates improving cash generation ability, which is essential for funding R&D and supporting strategic initiatives without relying heavily on external financing.

Bears Say

Profitability Challenges

Ongoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Operating Cash Flow

Negative operating cash flow suggests the company is not generating sufficient cash from its core operations, potentially limiting its ability to sustain growth and meet financial obligations.

Return On Equity

Negative return on equity reflects inefficiencies in using shareholder funds to generate profits, which could deter investors and affect the company's ability to raise capital.

Ryvu Therapeutics SA News

9Y4 FAQ

What was Ryvu Therapeutics SA’s price range in the past 12 months?
Ryvu Therapeutics SA lowest stock price was €3.11 and its highest was €6.98 in the past 12 months.
What is Ryvu Therapeutics SA’s market cap?
Ryvu Therapeutics SA’s market cap is €90.29M.
When is Ryvu Therapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ryvu Therapeutics SA’s earnings last quarter?
Ryvu Therapeutics SA released its earnings results on Sep 17, 2026. The company reported -€0.128 earnings per share for the quarter.
Is Ryvu Therapeutics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ryvu Therapeutics SA pay dividends?
Ryvu Therapeutics SA does not currently pay dividends.
What is Ryvu Therapeutics SA’s EPS estimate?
Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ryvu Therapeutics SA have?
Ryvu Therapeutics SA has 23,120,148 shares outstanding.
What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?
Ryvu Therapeutics SA reported an EPS of -€0.128 in its last earnings report. Following the earnings report the stock price went up 3.641%.
Which hedge fund is a major shareholder of Ryvu Therapeutics SA?
Currently, no hedge funds are holding shares in DE:9Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology